(+)-Medioresinol

(+)-Medioresinol is a furofuran-type lignan with antifungal and antibacterial properties. (+)-Medioresinol synergizes with antibiotics to exert antimicrobial and antibiofilm effects. (+)-Medioresinol induces intracellular ROS accumulation and mitochondrial-mediated apoptosis in Candida albicans. (+)-Medioresinol inhibits LPS (HY-D1056)-stimulated IL-12p40 production. (+)-Medioresinol is a PGC-1α activator that protects against endothelial cell pyroptosis in ischemic stroke via the PPARα-GOT1 axis. (+)-Medioresinol can be used in research on fungal and bacterial infection, inflammation, and ischemic stroke^{[1][2][3][4][5]}. In Vitro:(+)-Medioresinol (18 h) exerts antibacterial activity anginst E. faecium ATCC 19434, S. aureus ATCC 25923, P. acnes ATCC 6919, E. coli O-157 ATCC 43895, E. coli ATCC 25922, P. aeruginosa ATCC 27853, with MICs of 2.5, 5, 5, 5, 2.5, 20 µg/mL^[1].
(+)-Medioresinol has enhanced antibacterial effect against E. coli in combination with Cefotaxime (HY-A0088A) and Chloramphenicol (HY-B0239), synergistic effect against Staphylococcus aureus in combination with Ampicillin (HY-B0522) and Cefotaxime^[1].
(+)-Medioresinol (MIC/FIC x 1, x 4, x 10) inhibits biofilm formation against E. faecium ATCC 19434, S. aureus ATCC 25923, P. acnes ATCC 6919, E. coli O-157 ATCC 43895, E. coli ATCC 25922, P. aeruginosa ATCC 27853 in combination with Ampicillin, Cefotaxime, Chloramphenicol^[1].
(+)-Medioresinol exerts antifungal activity against C. albicans, C. parapsilosis, T. beigelii, M. furfur, with MICs of 3.125-6.25 µg/mL^[2].
(+)-Medioresinol (3.125 μg/mL, 2-4 h) arrests cells in G0/G1 phase, increases the accumulation of intracellular ROS levels, induces depolarization of MMP in C. albicans cells^[2].
(+)-Medioresinol (3.125 μg/mL, 2-4 h) induces mitochondrial release of Cyt c, metacaspase activation and DNA and nuclear damage, increases phosphatidylserine externalization and side scatter (SSC), decreases forward scatter (FSC) in C. albicans cells^[2].
(+)-Medioresinol (Compound 13) shows significant inhibitory activity on IL-12p40, with an IC₅₀ of 2 μM in LPS-stimulated BMDCs^[3].
(+)-Medioresinol (60-120 μM, 24 h) counteracts the decreased vitality and increased NT-proBNP levels caused by oxygen and glucose deprivation (OGD) in H9c2 cells^[4].
(+)-Medioresinol (60-120 μM, 24 h) reduces ROS, TNF-α, and IL-1β levels, increases PI3K, p-AKT, and p-mTOR levels in OGD H9c2 cells^[4].
(+)-Medioresinol (5-20 μM, 3-15 h) reduces the secretion of LDH, promotes the expression of PGC-1α and the protein expression of ZO-1 and Occludin, activates PGC-1α protected ischemia-induced brain injury in bEnd.3 cells^[5].
(+)-Medioresinol (20 μM, 15 h) inhibits pyroptosis of endothelial cells to protect the integrity of BBB by regulating phenylalanine metabolism and PGC-1α-mediated PAH and GOT1 expression in bEnd.3 cells caused by oxygen-glucose deprivation (OGD)^[5].
In Vivo:(+)-Medioresinol (1-10 mg/kg, i.v., at 2 h and 24 h after ischemia) exerts a protective effect on cerebral ischemia by inhibiting the pyroptosis of cerebral microvascular endothelial cells and protecting BBB integrity in male ICR mice model ^[5].
(+)-Medioresinol (1-10 mg/kg, i.v., at 2 h and 24 h after ischemia) promotes long-term functional recovery of mice with ischemia. in tMCAO mice model^[5].